Syndrome News and Research

RSS

Early surgery, timely treatment and prenatal diagnosis can help prevent oral clefts

Affecting more than 7,000 U.S. babies each year, cleft lip and/or cleft palate are the second most common birth defect, the cause of which continues to mystify scientists despite growing evidence of a complex interplay of genetic, environmental and lifestyle factors.

22 Apr 2011

Human placenta plays an active role in serotonin synthesis

Research at the Keck School of Medicine of the University of Southern California's Zilkha Neurogenetic Institute shows for the first time that the human placenta plays an active role in synthesizing serotonin, paving the way to new treatment strategies that could mitigate health impacts such as cardiovascular disease and mental illness.

22 Apr 2011

Coquitlam student earns top prize in 2011 British Columbia SABC competition

Ground-breaking research by a 17-year-old Coquitlam student who found a way to observe the effects of ethanol on early brain development in an intact and awake brain has earned him the top prize in the 2011 British Columbia sanofi-aventis BioTalent Challenge.

22 Apr 2011

March of Dimes honors Whitehead Institute Director for Developmental Biology work

Whitehead Institute Director David Page has been named a recipient of the 2011 March of Dimes Prize in Developmental Biology. The prize honors Page's groundbreaking body of research on the human Y chromosome.

22 Apr 2011

First Spouses support Down syndrome cognitive research

New Jersey Governor First Spouse Mary Pat Christie was joined by several other First Spouses from across the country in sponsoring the "Light the Way" event on March 21, 2011 to increase awareness of, and encourage support for, the rapidly advancing area of Down syndrome cognitive research.

21 Apr 2011

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients, compared to $117.6 million for the same period in 2010.

21 Apr 2011

Penn researchers explore the role of telomere caps in human aging

Researchers at the University of Pennsylvania School of Medicine are delving into the details of the complex structure at the ends of chromosomes.

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

How peppermint helps to relieve Irritable Bowel Syndrome

University of Adelaide researchers have shown for the first time how peppermint helps to relieve Irritable Bowel Syndrome, which affects up to 20% of the population.

20 Apr 2011

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

Obese patients may face high risk of complications after non-cardiac surgery

Obese patients with high blood pressure and diabetes are at much higher risk for major complications following non-cardiac surgery compared to otherwise healthy obese patients and patients of normal weight.

19 Apr 2011

Canada needs to modernize its pharmaceutical laws to ensure drug safety: CMAJ

Canada needs to modernize its pharmaceutical drug laws to ensure that new drugs as well as older drugs are safe for Canadians, states an editorial in CMAJ.

19 Apr 2011

Binge drinking can alter body's immune system response to orthopaedic injury

A Loyola University Health System study has found another reason to not binge drink alcohol.

19 Apr 2011

New biomarker-based test more effective for early acute kidney injury detection

A new biomarker-based diagnostic test is more effective than the current best practice for early detection of adverse outcomes after acute kidney injury, which can be fatal for an estimated 50 percent of the critically ill patients who get the condition.

19 Apr 2011

Nerve disorder expert Jack Griffin passes away

Jack Griffin, an internationally acclaimed and admired expert on diseases of the peripheral nervous system, founding director of the Johns Hopkins Brain Science Institute, and former director of Hopkins School of Medicine's Department of Neurology, died Saturday, April 16, after a long battle with bladder cancer. He was 69.

18 Apr 2011

Non-alcoholic fatty liver disease linked to coronary artery disease

Because of the prevalence of obesity in our country, many Americans are expected to develop a serious condition called non-alcoholic fatty liver disease (NAFLD), which can lead to cirrhosis, fibrosis, and in some cases liver failure. It is also one of the best predictors for coronary artery disease.

18 Apr 2011

Non-Hispanic black infants born with heart defects more likely to die within five years

Non-Hispanic black infants born with heart defects are more likely to die within the first five years of life than their non-Hispanic white and Hispanic peers. For certain types of congenital heart abnormalities, Hispanic children as well as non-Hispanic black children fare worse than non-Hispanic white children.

18 Apr 2011